DOA
PBYI icon

D'Orazio & Associates’s Puma Biotechnology PBYI Stock Holding History

D'Orazio & Associates’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$395K Sell
48,680
-1,235
-2% -$9.04K 0.05% 171
2026
Q1 		$319K Buy
49,915
+108
+0.2% +$696 0.04% 187
2025
Q4 		$296K Buy
49,807
+17,874
+56% +$94.9K 0.04% 194
2025
Q3 		$170K Buy
31,933
+16,906
+113% +$71.7K 0.02% 265
2025
Q2 		$51.5K Buy
+15,027
New +$48K 0.01% 276

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D'Orazio & Associates's PBYI Position: Q2 2026 in Review

D'Orazio & Associates reduced its Puma Biotechnology (PBYI) stake by 2.5% in Q2 2026, selling an estimated $9.04K and leaving 48,680 shares worth $395K. The position accounts for 0.05% of the portfolio, ranked #171.

D'Orazio & Associates first reported a position in PBYI in Q2 2025 and has held it in 5 quarters since. 160 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • D'Orazio & Associates held 48,680 shares of Puma Biotechnology worth $395K as of Q2 2026.
  • D'Orazio & Associates sold 1,235 Puma Biotechnology shares in Q2 2026, an estimated $9.04K.
  • Puma Biotechnology made up 0.05% of D'Orazio & Associates's portfolio in Q2 2026, its #171 holding.
  • D'Orazio & Associates first reported a position in Puma Biotechnology in Q2 2025 and has held it in 5 quarters since.
  • 160 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on D'Orazio & Associates's 13F filing for Q2 2026, filed 28 Jul 2026.